- $694.24m
- $733.01m
- $502.73m
Brief: Oncology Institute Q2 Revenue Rose 22.2% To $61 Mln
Brief: The Oncology Institute Announces $110 Mln Strategic Investment By Deerfield Management To Accelerate Expansion Into New Markets
Brief: Oncology Institute Continues Southern California Expansion
Brief: The Oncology Institute Set To Join The Russell 2000 And Russell 3000 Indexes
Brief: Oncology Institute- On May 11, 2022, Board Of Co Approved Share Repurchase Program With Authorization To Purchase Up To $20 Million Of Co’S Common Stock
Brief: The Oncology Institute Reports First Quarter 2022 Financial Results And Confirms Full Year 2022 Guidance
Brief: The Oncology Institute Names Mihir Shah As Chief Financial Officer
Brief: Oncology Institute Expands Riverside Location
Brief: The Oncology Institute Reports Q4 And Full Year 2021 Financial Results
Brief: The Oncology Institute Enters Into Value-Based Agreement With Maxheath
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:53 AM
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM
U.S. STOCKS ON THE MOVE-Ocugen, Biogen, Immunovant
NASDAQ RESUMED AT 09:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:43 AM
NASDAQ RESUMED AT 10:01 AM